Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOC: Erlotinib Prevention of Oral Cancer
NCT00402779Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2006
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of erlotinib in oral cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
oral cancer
Beyond the preview
Go deeper on NCT00402779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00402779.